Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

argenx SE - American Depositary Shares (NQ:ARGX)

791.59 +24.26 (+3.16%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today
argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 7.61% on an annualized basis producing an average annual return of 22.36%. Currently, argenx has a market capitalization of... 
Via Benzinga
Price Over Earnings Overview: argenx
In the current market session, argenx Inc. (NASDAQ: ARGX) share price is at $711.62, after a 0.07% increase. Moreover, over the past month, the stock decreased by 0.08%, but in the past year, went up... 
Via Benzinga
Pharma Tariffs Back In Spotlight On New Trump Threat
President Donald Trump threatened 100% tariffs on some drug imports. 
Via Investor's Business Daily
Topics ETFs Government World Trade
Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era
Johnson & Johnson (NYSE: JNJ) is making significant waves in the pharmaceutical landscape, announcing a trio of pivotal developments that underscore its robust pipeline and strategic focus on unmet... 
Via MarketMinute
12 Analysts Have This To Say About argenx
 
Via Benzinga
Is argenx Gaining or Losing Market Support?
 
Via Benzinga
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
argenx SE - ADR (NASDAQ:ARGX) Fits Louis Navellier's 'Little Book' Growth Strategy
Discover argenx SE (ARGX), a top growth stock meeting Louis Navellier's strict criteria with surging earnings, 97% revenue growth, and strong profitability. 
Via Chartmill
United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results
United Therapeutics also boasts a terrific 96 Composite Rating. The Composite score combines five separate proprietary ratings into one. 
Via Investor's Business Daily
Topics ETFs
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again
The company is working on a treatment for an autoimmune disease that affects the muscles. 
Via Investor's Business Daily
3 Healthcare Pathbreakers With Long-Term Tailwinds
These three firms in the fast-changing healthcare sector stand out to analysts for their strong product lineups, defensible technology, and notable pipelines. 
Via MarketBeat
Assessing argenx: Insights From 11 Financial Analysts
 
Via Benzinga
Where argenx Stands With Analysts
 
Via Benzinga
Earnings Scheduled For July 31, 2025
 
Via Benzinga
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today
 
Via Benzinga
Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win
Argenx advances Vyvgart with strong trial data in seronegative gMG, driving growth projections and reinforcing its leadership in IgG-driven diseases. 
Via Benzinga
Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data
Regeneron's Phase 3 NIMBLE trial showed cemdisiran improved myasthenia gravis symptoms, with an FDA filing expected in early 2026. 
Via Benzinga
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded
Additionally, the IBD SmartSelect Composite Rating for Argenx stock rose from 94 to a near best 96 Tuesday. 
Via Investor's Business Daily
Topics ETFs
Argenx Tops Buy Point On Bullish Study, 850 Price Target
Argenx announced positive study results and plans to seek FDA approval to expand its label for Vyvgart. ARGX stock jumped as RBC initiated coverage. 
Via Investor's Business Daily
argenx Earnings Preview
 
Via Benzinga
Argenx Targets FDA Label Expansion After Vyvgart Trial Success
Argenx reported positive Phase 3 Vyvgart data in seronegative myasthenia gravis, with plans for an FDA filing to expand the drug's label in 2025 
Via Benzinga
ARGENX SE - ADR (NASDAQ:ARGX) Ticks Key Boxes for Growth Investors Using Navellier's 'Little Book' Strategy
Discover ARGX, a top growth stock matching Navellier's criteria with explosive earnings growth, soaring sales, and a high 21% ROE. 
Via Chartmill
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today
 
Via Benzinga
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit
The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share. 
Via Stocktwits
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
 
Via Benzinga
FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls
FDA raised safety concerns for Vyvgart Hytrulo in CIDP, while Argenx moves ARGX-119 into late-stage trials for rare neuromuscular disease. 
Via Benzinga
Argenx Gets European Commission Approval For Drug To Treat Rare Autoimmune Disease, But Stock Fails To Garner Retail Attention
VYVGART for SC injection is available in vials or prefilled syringes and can be administered by a patient, caregiver, or healthcare professional. 
Via Stocktwits
Topics Artificial Intelligence
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.